(S1 (S (S (NP (NN Artemisinin)) (VP (VBZ inhibits) (NP (NN tumor) (NN lymphangiogenesis)) (PP (IN by) (NP (NP (NN suppression)) (PP (IN of) (NP (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (NN C))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBP have) (ADVP (RB previously)) (VP (VBN reported) (SBAR (IN that) (S (NP (NN dihydroartemisinin)) (VP (VBZ is) (VP (VBN found) (S (VP (TO to) (VP (VB have) (NP (DT a) (JJ potent) (NN ability)) (PP (IN in) (S (VP (VBG influencing) (NP (NP (JJ lymphatic) (JJ endothelial) (NN cell) (NN migration)) (CC and) (NP (NN tube) (NN formation)))))))))))))))) (. .)))
(S1 (S (S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBD investigated) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NN artemisinin))) (PP (IN on) (NP (NP (NP (NN tumor) (NN growth)) (, ,) (NP (NN lymphangiogenesis)) (, ,) (NP (NN metastasis)) (CC and) (NP (NN survival))) (PP (IN in) (NP (NP (NP (NN mouse) (NN Lewis) (NN lung) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN LLC)) (-RRB- -RRB-))) (NNS models)))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD found) (SBAR (IN that) (S (NP (ADJP (RB orally) (VBN administered)) (NN artemisinin)) (VP (VP (VBD inhibited) (NP (NP (NN lymph) (NN node)) (CC and) (NP (NN lung) (NN metastasis)))) (CC and) (VP (VBD prolonged) (NP (NN survival)) (PP (IN without) (NP (NN retarding) (NN tumor) (NN growth))))))))) (. .)))
(S1 (S (S (S (ADJP (JJ Consistent) (PP (IN with) (NP (NP (DT the) (NN decrease)) (PP (IN in) (NP (NP (NN lymph) (NN node)) (NN metastasis))))))) (, ,) (NP (NP (NP (NN tumor) (NN lymphangiogenesis)) (CC and) (NP (NN expression))) (PP (IN of) (NP (NP (NP (JJ vascular) (JJ endothelial) (NN growth) (NN factor)) (NN C)) (PRN (-LRB- -LRB-) (NP (NN VEGF-C)) (-RRB- -RRB-))))) (VP (VBD was) (ADVP (RB significantly)) (VP (VBN decreased) (PP (IN in) (NP (JJ artemisinin-treated) (NNS mice))) (, ,) (SBAR (IN as) (S (VP (VBN compared) (PP (TO to) (NP (NN control) (NNS mice))))))))) (. .)))
(S1 (S (S (ADVP (RB Furthermore)) (, ,) (NP (NP (JJ IL-1beta-induced) (NP (NP (NN p38) (JJ mitogen-activated) (NN protein) (NN kinase)) (PRN (-LRB- -LRB-) (NP (NN MAPK)) (-RRB- -RRB-))) (NN activation)) (CC and) (NP (NP (NN upregulation)) (PP (IN of) (NP (NP (NP (NN VEGF-C) (NN mRNA)) (CC and) (NP (NN protein))) (PP (IN in) (NP (NN LLC) (NNS cells))))))) (VP (VBD was) (ADVP (RB also)) (VP (VBN suppressed) (PP (PP (IN by) (NP (NN artemisinin))) (CC or) (PP (IN by) (NP (DT the) (NN p38) (NN MAPK) (NN inhibitor) (NN SB-203580)))) (, ,) (S (VP (VBG suggesting) (SBAR (IN that) (S (NP (NN p38) (NN MAPK)) (VP (MD could) (VP (VB serve) (PP (IN as) (NP (NP (DT a) (NN mediator)) (PP (IN of) (NP (JJ proinflammatory) (JJ cytokine-induced) (NN VEGF-C) (NN expression)))))))))))))) (. .)))
(S1 (S (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN artemisinin)) (VP (MD may) (VP (VB be) (ADJP (JJ useful) (PP (IN for) (NP (NP (DT the) (NN prevention)) (PP (IN of) (NP (NN lymph) (NN node) (NN metastasis)))))) (PP (IN by) (S (VP (VP (VBG downregulating) (NP (NN VEGF-C))) (CC and) (VP (VBG reducing) (NP (NN tumor) (NN lymphangiogenesis)))))))))))) (. .)))
